The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.
Legal claims defining the scope of protection, as filed with the USPTO.
4. The method of claim 1, wherein the anti-proliferative drug is administered as an inhaled formulation, topical formulation, during a bronchoscopy-based procedure, or systemically.
7. The method of claim 1, wherein the sample comprises morphologically normal tissues, or consists of morphologically-normal tissues or cells.
8. The method of claim 1, wherein the level of expression is the level of expression in a sample further comprising bronchial premalignant lesion cells.
9. The method of claim 1, wherein the subject is a smoker or former smoker.
10. The method of claim 1, wherein the bronchoscopy-based procedure and the chest CT scan are administered at a frequency of at least every 6 months.
11. The method of claim 10, wherein administering the bronchoscopy-based procedure and the chest CT scan to the subject at a frequency of at least every 6 months comprises instructing the subject to repeat the administration of the bronchoscopy-based procedure and the chest CT scan within 6 months.
12. The method of claim 1, wherein the at least one module 5 gene comprises at least RACGAP1 and TPX2; and the at least one module 6 gene comprises at least NEK11 and IFT88.
13. The method of claim 1, wherein the subject is one who does not presently have and has not previously had lung cancer.
15. The method of claim 14, wherein the level of expression of each of COX6A1; COX7A2; RACGAP1; TPX2; NEK11; IFT88; RPL26; and RPL23 is determined.
Cooperative Patent Classification codes for this invention. Click any code to explore related patents in that topic.
August 20, 2019
February 14, 2023
Browse 5M+ US patents with plain-English claim translations and AI-generated analysis.